<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02066103</url>
  </required_header>
  <id_info>
    <org_study_id>TSP0147</org_study_id>
    <secondary_id>5R42CA141907-03</secondary_id>
    <nct_id>NCT02066103</nct_id>
  </id_info>
  <brief_title>Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients</brief_title>
  <acronym>BROADWAY</acronym>
  <official_title>Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mercator MedSystems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mercator MedSystems, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the safety and feasibility of local oncological drug delivery into the bronchial wall&#xD;
      after recanalization of subjects with malignant airway obstruction. Safety and feasibility&#xD;
      (technical success) will be assessed.&#xD;
&#xD;
      This localized delivery is intended as an adjunct therapy and all subjects will receive&#xD;
      standard of care oncology therapy as determined by their treating physicians.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment safety</measure>
    <time_frame>12 weeks</time_frame>
    <description>Adverse Events (AEs), Serious Adverse Events (SAEs), and all Unanticipated Adverse Device Effects (UADEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Technical success</measure>
    <time_frame>procedure day</time_frame>
    <description>Device deployment and infusion success</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Airway patency improvements</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Malignant Airway Obstruction Secondary to Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Adequate bone marrow, liver, and renal function&#xD;
&#xD;
          -  Scheduled to undergo bronchoscopy for malignant airway obstruction as standard medical&#xD;
             care&#xD;
&#xD;
          -  Pathologically confirmed, unresectable primary or recurrent non-small cell lung cancer&#xD;
&#xD;
          -  Measurable disease with obstruction into the airway&#xD;
&#xD;
          -  Pathologically confirmed, unresectable primary or recurrent non-small cell lung cancer&#xD;
&#xD;
          -  Patients undergo recanalization procedure of tumor during bronchoscopy&#xD;
&#xD;
          -  Investigator is able to insert and deploy the Blowfish Catheter into the airway after&#xD;
             recanalization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Second primary malignancy, except for non-melanoma skin cancer and in situ cervical&#xD;
             cancer&#xD;
&#xD;
          -  Pregnant or nursing female subjects, or female subjects of child bearing potential who&#xD;
             refuse to take a pregnancy test prior to their enrollment in this study&#xD;
&#xD;
          -  Uncontrolled infection&#xD;
&#xD;
          -  Presence or recent history of any systemic disorder or conditions, such as:&#xD;
&#xD;
               -  uncontrolled hypertension&#xD;
&#xD;
               -  type 1 diabetes&#xD;
&#xD;
               -  severe pulmonary hypertension&#xD;
&#xD;
               -  acute kidney injury&#xD;
&#xD;
               -  stroke (within the last 6 month)&#xD;
&#xD;
               -  myocardial infarction (within the last 3 months)&#xD;
&#xD;
          -  Individuals with neurological, mental or psychiatric disorders&#xD;
&#xD;
          -  Concurrent participation in another study involving investigational drugs or&#xD;
             investigational medical devices&#xD;
&#xD;
          -  Other (non-cancer) disease not stabilized within 1 month before the Screening Visit&#xD;
&#xD;
          -  Known hypersensitivity to paclitaxel, Cremophor EL, or iodinated contrast media&#xD;
&#xD;
          -  Any serious, uncontrolled comorbidity or condition that an Investigator believes would&#xD;
             interfere with the intent of the study or would make participation not in the best&#xD;
             interest of the patient Intraoperative Exclusion Criteria&#xD;
&#xD;
          -  Use of pulmonary airway stents and/or ongoing or initiation of local external beam or&#xD;
             brachytherapy radiation&#xD;
&#xD;
          -  Any intraoperative complications that per the investigator's judgment increase the&#xD;
             risk to the patient.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>February 13, 2014</study_first_submitted>
  <study_first_submitted_qc>February 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2014</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Airway Obstruction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

